Resource Center

Media

For our Christmas and New Year’s holiday schedule, click here

From a single blood sample, the Karius Test can non-invasively and rapidly detect over 1000 pathogens causing both deep-seated and bloodstream infections.

Karius

ID Week 2021: The Karius Test Explained

Assistant Professor and Pediatric Intensivist at the University of California, San Diego and Rady Children's Hospital

Harnessing the Power of Microbial Cell-Free DNA in Plasma with the Karius Test to Detect Critical Infections

Founder and CSO

Science and Technology

Dr. David Berman, Medical Director at Karius, provides an overview of the Karius Test report and examples on how to interpret test results.

Medical Director at Karius

Interpreting the Karius Test Results

The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or hematocrit (HCT) with suspicion of pneumonia. Results are expected later in 2022.

Assistant Professor of Medicine, Director, Fellowship Training Programs, Pulmonary and Critical Care Medicine, Duke University Health System

Pneumonia in the Immunocompromised: Use of the Karius Test®  for the Detection of Undiagnosed Pathogens

The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or (HCT) with suspicion of pneumonia. Results are expected later in 2022. 

Assistant Professor of Medicine | Director, Fellowship Training Programs Pulmonary Diseases and Critical Care Medicine at Duke University

Use of the Karius Test in Immunocompromised Patients

Karius Mobile App - For Clinicians

Head of User Experience

Karius Portal 2.0

Patient Story: Brian

Director of the Kawasaki Disease Clinic Rady Children's Hospital - San Diego

Infections Mimicking Systemic Inflammatory Diseases

Senior Director, Medical Advisor at Karius, Professor Emeritus, Department of Pathology and Laboratory Medicine, Medical University of South Carolina

Enhanced Clinical Metagenomic Testing: A Non-Invasive Liquid Biopsy for Infectious Diseases from Karius

Patient Story: Ryan

Assistant Professor of Medicine Transplant Infectious Diseases University of Colorado

Media

Stay up-to-date with Karius